Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-09T19:43:43.712Z Has data issue: false hasContentIssue false

152 - Zonisamide

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Zonegran

Generic?

• Yes

Class

• Antiepileptic drug (AED), structurally a sulfonamide

Commonly Prescribed for

(FDA approved in bold)

Partial-onset seizures (adjunctive in adults)

• Partial-onset seizures (adjunctive in pediatric patients)

• Primary generalized tonic-clonic seizures (adjunctive; adults and pediatric patients age 2–16)

• Myoclonic epilepsy, Lennox-Gastaut syndrome, absence seizure

• Infantile spasms (West syndrome)

• Idiopathic intracranial hypertension

• Migraine prophylaxis

• Adjunct to levodopa for Parkinson's disease

• Obesity

• Binge-eating disorder/bulimia

• Tardive dyskinesias

• Neuropathic pain

How the Drug Works

Unknown but there are multiple mechanisms of action that may be important

• Sodium channel antagonist

• Modulates N-, P-, and T-type calcium channels

• Binds to GABA receptors

• Weak carbonic anhydrase inhibitor

• Monoamine oxidase (MAO)-B inhibition

• May help facilitate dopamine and serotonin neurotransmission

How Long Until It Works

• Seizures: by 2–3 weeks

• Migraines: can take up to 3 months on a stable dose to see full effect

If It Works

• Seizures: goal is the remission of seizures. Continue as long as effective and well tolerated. Consider tapering and slowly stopping after 2 years seizure-free, depending on the type of epilepsy

• Migraine: goal is a 50% or greater reduction in migraine frequency or severity. Consider tapering or stopping if headaches remit for more than 6 months or if patient considering pregnancy

If It Doesn't Work

• Increase to highest tolerated dose

• Epilepsy: consider changing to another agent, adding a second agent, using a medical device, or a referral for epilepsy surgery evaluation. When adding a second agent, keep drug interactions in mind

• Migraine: address other issues such as medication overuse, other coexisting medical disorders, such as anxiety, and consider changing to another agent or adding a second agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For some patients with epilepsy or migraine, low-dose polytherapy with 2 or more drugs may be better tolerated and more effective than high-dose monotherapy

• Epilepsy: keep in mind drug interactions and their effect on levels

• Migraine: consider β-blockers, antidepressants, natural products, other AEDs, and non-medication treatments, such as biofeedback, to improve headache control

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 561 - 564
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Zonisamide
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.153
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Zonisamide
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.153
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Zonisamide
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.153
Available formats
×